pattern was the most common followed by speckled (29.9% and 13.4% respectively). Anticardiolipin antibodies was positive in 71.2% while lupus anticoagulant was detected in 50.8% (table 2). Mean SLEDAI was 13.38±9.75 with proteinuria in 58.9%, increased binding to DNA in 54.9% and low complement in 45.5%.

Abstract AB0625 – Table 1. Renal biopsy of 268 Egyptian SLE patients

Renal Biopsy	Frequency	Percent
Not done	301	52.9
Class I LN	23	4.0
Class II LN	34	6.0
Class III LN	104	18.3
Class IV LN	80	14.1
Class V LN	20	3.5
Class VI LN	7	1.2

Abstract AB0625 – Table 2. Immunological pattern of 569 Egyptian SLE patients

	Number	Percent
ANA pattern	313	55
- Not done	170	29.9
- Homogenous	76	13.4
- Speckled	10	1.8
- Rim		
Anti-ds DNA	488	85.8
Anticardiolipin antibodies	405	71.2
Lupus anticoagulant	289	50.8
Anti-Ro antibodies	16	2.8
Anti-La antibodies	12	2.1

Abstract AB0625 – Figure 1

Conclusions: These data are similar to that reported from MENA region; however, with little difference from international data as regard presenting symptom and immunological pattern. Differences observed among ethnic groups probably reflect the genetic component of ethnicity.

REFERENCES:

- [1] Mills JA. Systemic lupus erythematosus. *New Engl J Med* 1994;330:1871–1879.
- [2] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum.* 1997;40:1725.
- [3] Bombardier C, Gladman D, Urowitz M, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. *Arthritis Rheum* 1992;35:630–640.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.4244

AB0626

CLINICAL FEATURES OF SYSTEMIC LUPUS ERYTHEMATOSUS IN MALES

S. Sayhi, T. Ben Achour, N. Boussetta, B. Arfaoui, N.E.H. Gueddich, F. Ajili, B. Louzir, on behalf of research unit UR 17DN02. *internal medicine, Military hospital, Tunis, Tunisia*

Background: Systemic lupus erythematosus (SLE) is an autoimmune disease that primarily affects the adult woman. Male involvement is rare.

We report a series of men with systemic lupus in order to specify the particularities of the different manifestations of SLE in men.

Objectives: we aim to describe the clinical feature of male tunisien patients presenting SLE

Methods: This is a retrospective study of male lupus patients hospitalised in internal medicine for a period of 9 years. All patients are Tunisian and meet the lupus criteria established by the ACR.

Results: Twenty-one patients with male lupus were enrolled in a total of 97 systemic lupus (gender-to-sex ratio 3.6). The mean age at diagnosis was 34 years (range: 14 to 84 years). A family 1 lupus in one case. The clinical manifestations are dominated by joint damage (95%) with non-erosive arthritis in 9 cases and arthralgia in 12 cases, followed by cutaneous manifestations (erythema vespertilio=71%, photosensitivity=41%), Raynaud (25%). Pericarditis was found in 37.5% and pleurisy in 23%. Venous thrombosis was only observed in 4 cases associated with anti-cardiolipin antibodies in one case, and complicated by pulmonary embolism in one case. Sixteen patients had progressive nephropathy (permanent proteinuria >0.5 g/24 hours with mean proteinuria of 3.2 g/24 hours and extremes of 0.7 and 8 g/24 hours) of which 9 underwent kidney biopsy puncture. Membranoproliferative glomerulonephritis was observed in 4 cases, segmental and focal in 3 cases, mesangial and extramembranous, each in one case. Two patients had progressed to end-stage renal disease requiring hemodialysis. Concerning haematological involvement, anaemia, observed in 50% of cases, was haemolytic in 12.5% of cases. Leukopenia and lymphopenia were each scored in 46% of cases. Sixteen patients 16 were put on chloroquine, all patients were placed on high dose corticosteroids for an average of 25 months with boli in 7 cases, combined with cyclophosphamide (700 mg/month IV) in 4 patients cases in patients with proliferative glomerulonephritis. The evolution was enlabeled with flares in 11 cases, 2 of which had progressed to end-stage renal failure. Aseptic osteonecrosis of the femoral head was observed in one patient after 1 year of corticosteroid therapy. Complete remission was observed in 3 patients with a follow-up of 14, 24, and 144 months and one patient died as a result of peritonitis.

Conclusions: Systemic lupus is a disease essentially of adult women and rarely affects humans. The prevalence of the disease in the female gender suggests the intervention of a hormonal factor. In favour of the deleterious role of estrogens, lupus relapses are triggered by pregnancy, the peri and postpartum, as well as the oostropogestative pill. The most common manifestations in humans in our study were renal impairment including membranoproliferative glomerulonephritis and segmental and focal glomerulonephritis complicated by renal failure in two patients. These data join those of the literature. The same is true for hemolytic anaemia.

LES is rare in men, nevertheless it correlates with a higher mortality in front of the association most frequent with the renal involvement which imposes a better knowledge of these clinical and laboratory particularities.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.5787

AB0627

PHYSICAL ACTIVITY BY SELF-REPORTED PHYSICAL ACTIVITY AND LUPUS NEPHRITIS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

S.-K. Kim, J.-Y. Choe, S.-H. Park, H. Lee. *Catholic University of Daegu School of Medicine, Daegu, Korea, Republic of Ireland*

Background: Physical activity is found to be associated with clinical status such as disease activity, organ damage, disability, fatigue, and quality of life in systemic lupus erythematosus (SLE).

Objectives: The aim of this study was to identify the association between physical activity and disease activity and organ damage in patients with SLE.

Methods: A total of 415 patients with SLE were consecutively enrolled from KOREan lupus Network (KORNET) registry. This registry assessed clinical features, disease activity Systemic Lupus Erythematosus Disease Activity Index 2000 [SLEDAI-2K]), and disease damage (Systemic Lupus International Collaborating Clinics/American College of Rheumatology [SLICC/ACR] damage index [SDI]) at the enrollment of study. Self-reported physical activity was measured by International Physical Activity Questionnaire (IPAQ). Statistical analyses were used by Mann-Whitney U test and multivariate logistic regression analysis.

Results: There is significant difference of vigour activity between patients with lupus nephritis (n=93) and without lupus nephritis (n=322) (p=0.012), but not moderate and walking activities. In contrast, the differences of each physical activity,

walking, moderate, and vigorous intensity, according to SLEDAI-2K and SDI were not found. In addition to high PCS of SF-36 ($p=0.006$) and SLEDAI-2K ($p=0.038$), less vigorous physical activity were related with lupus nephritis ($p=0.033$). However, the risk of CVD was not associated with physical activity of SLE.

Conclusions: This study showed that patients with lupus nephritis had less vigorous physical activity. It implicates that SLE-related organ damage might be associated with levels of physical activity.

REFERENCES:

- [1] Costenbader KH, Wright E, Liang MH, Karlson EW. Cardiac risk factor awareness and management in patients with systemic lupus erythematosus. *Arthritis Rheum* 2004;51:983–8.
- [2] Katz P, Julian L, Tonner MC, Yazdany J, Trupin L, Yelin E, Criswell LA. Physical activity, obesity, and cognitive impairment among women with systemic lupus erythematosus. *Arthritis Care Res (Hoboken)* 2012;64:502–10.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.3585

AB0628

INFECTIONS IN HOSPITALISED PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS- A PROSPECTIVE OBSERVATIONAL STUDY FROM A TERTIARY CARE CENTRE IN SOUTHERN INDIA

S. Alur¹, M.M. Thabab¹, V.S. Negi², S. Sistla³. ¹Medicine; ²Clinical Immunology; ³Microbiology, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry, India

Background: Infections are one of the main causes of morbidity and mortality in SLE.¹ The high prevalence of infection is attributed to use of immunosuppressive agents and disease activity. There is paucity of literature from India on infections, types of infections, predictors and outcome.

Objectives: To determine the frequency, types and determinants of major infections in hospitalised patients with SLE.

Methods: Patients with SLE (2012 SLICC-ACR criteria) aged ≥ 13 years, admitted to Clinical Immunology and Medicine wards were included. Clinical evaluation for major organ involvement of SLE, disease activity was assessed by SLEDAI-2K. Whenever there was a suspicion of infection appropriate work up to find the etiology of infections was done. Major infection was defined as presence of either one of the following a) sepsis b) pneumonia, or pyelonephritis, or endocarditis, or meningitis. c) skin or soft tissue infection requiring hospital admission for treatment d) Infection requiring IV antibiotic therapy. The diagnosis of infection was made by compatible clinical, microbiological and imaging criteria.

Results: From December 2016 till January 2018, 63 (55 women and 8 men) were included; Mean age was 28.8 ± 9.8 years; mean SLEDAI-2K was 14.6 ± 7.03 . Median duration of hospital stay was 14 days; range 2–64 days. Disease manifestation (including present and ever present) were arthralgia/arthritis in 51 (81%), oral ulcers 56 (88.9%), myositis 10 (15.9%), lupus nephritis 35 (55.6%), CNS lupus 14 (22.2%), serositis 14 (22.2%), cardiac involvement 13 (20.6%), APS 3 (4.8%). At the time of enrollment thrombocytopenia was present in 13 (20.6%), and leukopenia 11 (17.5%).

Twenty-three of 63 (36.5%) had infections (table 1), 14/23 (60.8) were microbiologically proven, remaining (39.2%) were confirmed by compatible clinical features and imaging.

Seven of 63 (11.1%) died; 5 (21.7%) in the infection group versus 2 (5%) in no infection group, $p=0.08$ OR 5.58 [CI 0.98–31.7]. Thirty-four of 63 (54%) had fever on admission; 17/23 (74%) patients with infection had fever compared to 17/40 (42.5%) in no infection group, $p=0.02$ [OR=3.8, CI 1.2–11.7]. There was no association of lupus nephritis, CNS lupus, leukopenia, receipt of cyclophosphamide, rituximab, methylprednisolone pulse therapy with occurrence of infection.

Abstract AB0628 – Table 1. Infections in SLE patients

Type of Infections	n=23 (%)
Bacterial Pneumonia	3 (13.7)
Fungal Pneumonia	2 (8.7)
(Invasive Aspergillosis)	
Pulmonary tuberculosis	2 (8.7)
Disseminated tuberculosis	2 (8.7)
Urinary tract infection	4 (17.4)
Skin and soft tissue infection	4 (17.4)
Blood stream infections	3 (13)
Suspected brain abscess	1 (4.3)
Pyogenic meningitis	1 (4.3)
Disseminated Varicella	1 (4.3)
Viral bronchiolitis	1 (4.3)

Conclusions: Almost 36% of SLE patients in hospital have infections. There appeared to be an increase in number of deaths among patients with infections. There was no association of infections with the dose of prednisolone or previous immunosuppression with cyclophosphamide.

REFERENCE:

- [1] Shyam C, Malaviya AN. Infection-related morbidity in systemic lupus erythematosus: a clinico-epidemiological study from northern India. *Rheumatol Int.* 1996; 16: 1–3.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.1383

AB0629

PREVALENCE OF ASYMPTOMATIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS

S. Shkireeva^{1,2}, O.M. Lesnyak¹, E.G. Zotkin². ¹North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg; ²Research Institute of Rheumatology named after V.A. Nasonova, Moscow, Russian Federation

Objectives: To investigate the prevalence of vertebral fractures and to identify risk factors associated with vertebral fractures in postmenopausal women with systemic lupus erythematosus (SLE).

Methods: 86 consecutive postmenopausal women with SLE were included in this study. Bone mineral density (BMD) measurements of the hip and spine were performed using the dual energy X-ray absorptiometry (DEXA). Vertebral fracture assessment (VFA) was done for detection vertebral fractures using a method described by Genant. Accumulated damage was scored using the SLICC/ACR damage index (SDI).

Results: Vertebral fractures were defined in 42 (48.8%) postmenopausal women with SLE. Half of all patients with SLE ($n=22$, 25.6%) had asymptomatic vertebral fractures which were diagnosed only in this study. Every patient had 1.7 vertebral fractures on average (from 0 to 4). Distribution of vertebral fractures along the spine showed one peak at Th7. Univariate analyses of variables associated with fractures were longer duration of postmenopausal status in women with SLE, longer glucocorticoids intake, higher cumulative dose of glucocorticoids, higher SDI, lower BMD of the spine. Multivariate analysis showed longer duration of postmenopausal status in women with SLE (odds ratio 4.05, $p=0.007$), cumulative dose of glucocorticoids ≥ 60000 mg of prednisone (odds ratio 3.68, $p=0.009$), SDI ≥ 7 (odds ratio 2.94, $p=0.028$) and low BMD ($T \leq -2.0$) of the spine (odds ratio 2.48, $p=0.015$) were significantly associated with vertebral fractures in the thoracic and/or lumbar spine.

Conclusions: Vertebral fractures were occurred in 48.8% of postmenopausal women with SLE and half of them were asymptomatic. The current method using DEXA to predict the presence of vertebral fracture has limited value and there is a need for assessment of bone quality. Vertebral morphometry in patients with SLE is recommended and early therapeutic intervention is necessary to prevent vertebral fractures in postmenopausal women with SLE.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.5498

AB0630

EXPRESSION OF TNF-A AND IL-6 IN SYSTEMIC LUPUS ERYTHEMATOSUS: RELATIONSHIP WITH DISEASE ACTIVITY

T.A. Panafidina, T.V. Popkova, A.A. Novikov, E.L. Nasonov. V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation

Background: Cytokines play an important role in the pathogenesis of SLE. TNF- α , IL-6 are the cytokines with suggested proinflammatory and immunoregulatory actions in the pathogenesis of SLE with differential effects on B or T cells, as well as on programmed cell death. Fas/APO-1 and Fas ligand (FasL) are involved in the apoptosis. FasL is a marker of apoptosis, it induces cell apoptosis when binds to Fas/APO-1. Both are expressed in membrane-associated and soluble forms (sFas/APO-1 and sFasL). sFas/APO-1 is known to inhibit the apoptosis via blocking the binding of Fas/APO-1 to FasL/sFasL.

Objectives: We evaluated the levels of IL-6 and TNF- α and their possible association with disease activity, apoptosis markers.

Methods: The study included 52pts (89% female, age 30.0 [26.5–44.5 years] (median [interquartile range 25% >75%])) with SLE ACR, 1997 and 20 controls (100% female without any rheumatic and infectious diseases, age 30.0 [25.0–39.5 years]). SLE-related factors, including disease duration, clinical features, SLE Disease Activity Index (SLEDAI 2K) and Systemic Lupus International Collaborating Clinics (SLICC) damage index were evaluated in parallel with relevant laboratory findings, autoantibodies. Serum levels of IL-6 and TNF- α (pg/ml), sFas/